HomeNews

News

  • Phase 1 study of TRV250, for acute migraine, successfully completed by Trevena

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New dose formulation for Nuplazid, in Parkinsons, approved by FDA

    • July 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • α-Linolenic acid can reduce disease activity in multiple sclerosis patients, study finds

    • June 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Novartis presents new Aimovig data to reinforce its efficacy, safety and tolerability

    • June 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New Migraine study, by Novartis, indicates decreased workplace efficiency of patients

    • June 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New mobile app can help MS patients manage their disease better

    • June 28, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Impel Neuropharma to present acute migraine treatment drug data at AHS 2018

    • June 28, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Lilly to present Galcanezumab and Lasmiditan Ph 3 data at AHS 2018

    • June 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • ORYZON announces First Patients in Alzheimer’s trial in UK

    • June 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • AARP Invests $60 Million for Cures to Dementia and Alzheimer’s research

    • June 27, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more